邁瑞醫療收購全球知名免疫原料供應商HyTest
國內醫療器械行業龍頭邁瑞醫療正在加速佈局IVD上游原材料市場。
5月16日，邁瑞醫療發佈公吿稱，公司擬通過全資子公司邁瑞全球(香港)有限公司及香港全球的全資子公司Mindray Medical Netherlands B.V.以現金形式收購Hytest Invest Oy(下文稱"標的公司")及其下屬子公司100%股權。
公吿顯示，收購主要包括四個部分：(1)Summa Equity AB下屬基金和Spartak Co-Investment AB持有的標的公司100%股權；(2)由Maria Severina和Alexey Katrukha以及若干自然人股東在標的公司的子公司Hytest Holding Oy中持有的全部少數股權；(3)由Maria Severina和Jukka Lehikoinen在標的公司間接子公司Hytest Oy中持有的全部少數股權；(4)部分個人股東及自然人持有的Hytest Holding Oy公司4790643股期權。
上述交易完成後，邁瑞醫療將間接持有Hytest Invest Oy及其下屬子公司100%的股權。此次收購總價預計約為5.45億歐元，最終交易金額以實際交割時確認為準。
據瞭解，HyTest成立於1994年，總部位於芬蘭舊都Turku，研發及生產基地位於莫斯科，是全球知名的免疫原材料供應商，主要產品包括單克隆抗體、抗原及血漿製品。
2020年，HyTest實現營業收入2800萬歐元，營業利潤1300萬歐元，利潤率近50%。受到財務費用支出的影響，HyTest2020年淨利潤為657萬歐元，淨利率達23%。邁瑞醫療完成併購後，HyTest的貸款有望得到償還，從而降低該公司的財務費用。
今年一季度，HyTest實現營業收入約930萬歐元；營業利潤約490萬歐元，利潤率超過50%；淨利潤290萬歐元，淨利率超31%。
體外診斷業務是邁瑞醫療的核心業務板塊之一，2020年該業務在總營收的佔比達31.61%。
邁瑞醫療在公吿中稱，公司需進一步加強化學發光產品及原料的核心研發能力建設，優化上下游產業鏈的全球化佈局；本次交易有利於公司更好地整合資源，完善化學發光產品研發及供應鏈平台建設，符合公司長遠發展規劃及全體股東利益。
據醫療器械行業資深從業者介紹，核心原材料對於IVD下游業務至關重要，實現核心原料的自研有利於邁瑞醫療IVD業務的質量控制、成本優化和供應安全。同時，由於HyTest在全球免疫原材料領域的卓越地位，收購完成後，邁瑞醫療將一躍成為這一領域的頭部企業。
事實上，邁瑞醫療與HyTest已經有十多年的合作歷史。邁瑞醫療總裁吳昊表示，希望在交易完成後，HyTest把更多資源投入到持續的技術和產品開發中，進一步強化技術創新和學術探索，以更高性能和質量的產品服務全球IVD客户。
"我們將堅定支持HyTest不斷加大研發投入，持續鞏固和提升核心競爭力，保持在專業IVD上游原材料領域的世界領先地位。"吳昊説。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
